Department of Urology, Yongin Severance Hospital, Urological Science Institute, Yonsei University Health System, Yongin, Korea.
J Sex Med. 2011 Nov;8(11):3214-9. doi: 10.1111/j.1743-6109.2011.02364.x. Epub 2011 Jun 23.
The adverse effects of long-term drug therapy for prostate cancer (PCa) can dramatically impact patient quality of life and are considered to be important factors when selecting treatment.
To assess stretched penile length before and after long-term androgen deprivation therapy (ADT) for treatment of PCa.
From January 2008 to June 2010 at a single institution, 39 consecutive patients without distant metastases who were elected to receive ADT as initial therapy for PCa were prospectively enrolled. Exclusion criteria were history of penile anomalies and/or trauma, and prior radical prostate surgery or radiation therapy. Erectile functions were evaluated at baseline according to the International Index of Erectile Function (IIEF). Vertically stretched penile length was measured every 3 months from the pubopenile junction to the meatus with a spring scale.
After ADT, significant 3-month interval changes in stretched penile length were noted for up to 15 months (P < 0.001). The relationship between potency and penile shortening was not significant (P = 0.45).
The mean patient age was 67.1 years. Before therapy, the mean stretched penile length was 10.76 cm. After 24 months of ADT, mean penile length had decreased to 8.05 cm. However, these changes plateaued after 15 months. Normal erectile function (EF) was reported by 41% of patients before therapy, while 10.5% reported normal EF at the 24-month follow-up. The relationship between potency and penile shortening was not significant. However, patients who preserved their potency tended to experience less penile shortening.
The administration of luteinizing hormone-releasing hormone (LHRH) agonists induced significant decreases in penile length for only up to 15 months in the absence of the confounding effects of surgery and radiation.
长期前列腺癌（PCa）药物治疗的不良反应会严重影响患者的生活质量，在选择治疗方法时被认为是重要的因素。
评估长期雄激素剥夺治疗（ADT）治疗 PCa 前后的伸展阴茎长度。
2008 年 1 月至 2010 年 6 月，在一家机构中，39 例连续的无远处转移的患者入选，他们被选为接受 ADT 作为初始治疗 PCa 的初始治疗。排除标准为阴茎异常和/或外伤史，以及先前的根治性前列腺手术或放射治疗。根据国际勃起功能指数（IIEF），在基线时评估勃起功能。使用弹簧秤从耻骨联合到尿道口测量阴茎的垂直伸展长度，每 3 个月测量一次。
ADT 后，伸展阴茎长度在长达 15 个月的时间内有显著的 3 个月间隔变化（P<0.001）。勃起功能与阴茎缩短之间的关系无显著性差异（P=0.45）。
患者的平均年龄为 67.1 岁。治疗前，平均伸展阴茎长度为 10.76 厘米。ADT 24 个月后，阴茎长度平均降至 8.05 厘米。然而，这些变化在 15 个月后趋于稳定。治疗前有 41%的患者报告有正常勃起功能（EF），而在 24 个月的随访中有 10.5%的患者报告有正常 EF。勃起功能与阴茎缩短之间的关系无显著性。然而，保持勃起功能的患者往往经历较少的阴茎缩短。
在没有手术和放射治疗的混杂影响的情况下，促黄体生成素释放激素（LHRH）激动剂的给药仅导致阴茎长度在长达 15 个月的时间内显著下降。
